Agios Pharmaceuticals, Inc.
AGIOAgios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 (or 2007) by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.: Table 1
Drugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Jul 30, 2026
27dMarket Overview
Stock performance and key metrics
1 upcoming, 1 past
How AGIO's past catalysts played out
Pyruvate Kinase Deficiency
2 drugs in this indication
Sickle Cell Disease
2 drugs in this indication
Myelodysplastic Syndromes
1 drug in this indication
Non-Transfusion-dependent Alpha-Thalassemia
1 drug in this indication
Pediatric Pyruvate Kinase Deficiency
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Agios Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Agios Pharmaceuticals, Inc.'s (AGIO) pipeline across Phase 3, Phase 2. Its lead program is Mitapivat (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Agios Pharmaceuticals, Inc.'s next FDA catalyst?→
Agios Pharmaceuticals, Inc.'s (AGIO) next tracked catalyst is a Earnings expected July 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track AGIO biotech catalysts?→
Add AGIO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Agios Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.